BioArctic

BioArctic Accounts Payable

The Accounts Payable of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 23.94 M SEK. In the previous year, Accounts Payable was 50.45 M SEK — a change of -52.55% (lower).

Accounts Payable

23.94 MSEK

YoY

-52.55%

Last updated:

Accounts Payable of BioArctic is 2025 23.94 M SEK. Accounts Payable of BioArctic was 2024 50.45 M SEK. It decreases by -52.55% lower compared to the previous year.

The BioArctic Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
14.81 M SEK
Jan 1, 2019
8.22 M SEK
Jan 1, 2020
14.31 M SEK
Jan 1, 2021
11.82 M SEK
Jan 1, 2022
21.49 M SEK
Jan 1, 2023
29.87 M SEK
Jan 1, 2024
50.45 M SEK
Jan 1, 2025
23.94 M SEK
The BioArctic Accounts Payable history
YEARAccounts PayableYoY
23.94 MSEK-52.55%
50.45 MSEK+68.93%
29.87 MSEK+38.97%
21.49 MSEK+81.85%
11.82 MSEK-17.42%
14.31 MSEK+74.14%
8.22 MSEK-44.50%
14.81 MSEK+95.20%
7.59 MSEK-35.36%
11.74 MSEK+916.10%
1.16 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Accounts Payable of BioArctic is 23.94 M SEK in 2025.

Accounts Payable of BioArctic changed from 50.45 M SEK to 23.94 M SEK, representing a -52.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable BioArctic since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic